about
Beta-thalassemiaClinical and molecular analysis of haemoglobin H disease in Sardinia: haematological, obstetric and cardiac aspects in patients with different genotypesPregnancy and beta-thalassemia: an Italian multicenter experience.Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxA genetic score for the prediction of beta-thalassemia severity.Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadDefining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.β-Thalassemia.Liver iron concentrations and urinary hepcidin in beta-thalassemia.Onset of cardiac iron loading in pediatric patients with thalassemia major.Thalassemia major between liver and heart: Where we are now.Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.A decisional algorithm to start iron chelation in patients with beta thalassemiaDifferences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermediaEfficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up.Natural history of hepatitis C in thalassemia major: a long-term prospective study.Cholelithiasis in thalassemia major.Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major.Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.Osteoporosis in beta-thalassemia: Clinical and genetic aspects.Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia.Current growth patterns in children and adolescents with thalassemia major.Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia.Thalassemia Major: Who Is Afraid of Serum Ferritin below 500 μg/l?Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective studyInvestigating the Alpha1 Nco I Mutationα-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia.Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatmentNo evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermediaOnce-daily oral deferasirox for the treatment of transfusional iron overloadSudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemiaSeasonal variation of pretransfusion hemoglobin levels in patients with thalassemia majorNew case of contiguous gene syndrome at chromosome 8p11.2p12Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional studyInfluence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis
P50
Q21202886-9622262A-8CE8-46E6-8BD3-4589E30DC63AQ28275797-DA6E1393-9BB9-484E-9BFD-3700A9DFA583Q33707385-22B276C8-4242-4F1D-B390-F66BDCBD4F25Q34516223-01C2817E-9848-4773-92BB-D24F893C8C5AQ35236041-C82F63EC-0987-462B-90A9-01C663B9252CQ35813192-E4A07149-1103-4996-AEEB-E6B95334A8DAQ38423854-7C7165C7-7252-40A8-9083-07E3C5E5D2D9Q38433834-902A851B-5A09-4796-A13B-037D6C3EDCA1Q38998151-DF2A0566-FB15-48D8-97CF-04F0B25B6348Q40214945-B471C261-ECA2-4533-8E38-4F6AF5A66944Q41491287-8A4A978F-ADCF-4EAD-95A8-0024DA13949CQ41737208-44AFD266-DC36-4347-8746-C7449DF7C4C1Q41934079-DFC85CEF-C4DC-464E-A2CA-3CC389E776FEQ42000881-A9EB5D54-AA9C-40DC-9160-EAFB317ACDBAQ42573868-89E52CA3-B5E5-4222-A496-92B150F78D0EQ42632211-46886216-06DB-4F5C-B87E-B0B73D5736AAQ42989273-8E0AA495-BFDD-4AE8-B0EE-EFB77B39AC6EQ43859596-A456E3F4-E0F8-4B60-A9B9-2B36F999338AQ44236897-F3178D13-1208-43D2-8D80-69D66975A398Q46598299-943F4D19-59C6-42B7-B885-272D93E08D93Q46748354-105B4594-AFC2-4D2D-BC56-566B661B67F3Q46844111-F5808B2F-0C10-4F7C-BB0C-B84132996D2AQ47908871-ADD33392-90BF-4FDD-AECF-AF7C0BC8B750Q48303363-33AF6EAB-65D8-47F5-9C32-04B0F5958138Q48352356-90630A0D-C29F-429C-8F10-30D88C8AAAC7Q61776592-B6701454-FD8E-4FAE-8D19-88948B8CE759Q61776598-93443817-AEDF-4208-8017-9D907591961DQ61776600-6F5755A2-D894-4768-9103-309F0004B10CQ61776605-51BE924E-A09D-4AE9-9D98-48754A1CBA89Q61776606-B7B39D3B-867A-4EC1-8C39-DC129D5A8379Q61776616-C3975A5B-89F1-4EDE-92A5-D12B19000F3DQ61776618-75FCE254-C0DB-4CE6-9BE0-B6D4D66C0BBEQ61776624-B847BAFA-1997-404F-B173-C1D94101BE43Q61776627-40236216-8D0D-4B3D-A7A7-1550C444B6EAQ61776629-6D72A9C5-ADAE-4F43-BD04-889EFE512302Q89160856-4003C85E-F901-48A0-BB59-4894199F7DCDQ91134769-5973D05C-FEC0-4108-BEB7-17F764F1EBC3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Raffaella Origa
@ast
Raffaella Origa
@en
Raffaella Origa
@es
Raffaella Origa
@nl
Raffaella Origa
@sl
type
label
Raffaella Origa
@ast
Raffaella Origa
@en
Raffaella Origa
@es
Raffaella Origa
@nl
Raffaella Origa
@sl
prefLabel
Raffaella Origa
@ast
Raffaella Origa
@en
Raffaella Origa
@es
Raffaella Origa
@nl
Raffaella Origa
@sl
P106
P1153
23009790400
P21
P31
P496
0000-0002-2346-9616